Skip to main content

Table 3 Pathological response to SBRT and the correlation between clinical response

From: Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series

Patient Pre-LT SBRT LT
BCLC stage Dose (Gy)/fraction number Prescription isodose/maximum dose* Radiological response RILD Milan criteria Median time to LT (months) Donor type Pathologic AJCC 8th stage Max. tumor size PVTT Tumor necrosis Recurrence site Status
1 B 42/5 75%/5600 cGy SD B → B 1.6 CLT IIIA 2.5 Present 30% DOO
2 B 60/5 72%/8333 cGy PR B → B 34.3 LDLT II 2.2 5% Liver, carcinomatosis DOD
3 B 45/5 75%/6000 cGy SD B → B 7.3 LDLT II 2.5 100% Liver DOD
4 B 40/5 70%/5714 cGy SD B → B 5.8 LDLT II 6 99% NED
5 A 50/5 80%/6250 cGy PR W → W 17.0 CLT II 2.5 100% NED
6 C 55/5 73%/7534 cGy PR B → B 4.0 LDLT II 3.5 Present 10% Bilateral lung DOD
7a
b
A
B
45/5
45/5
79%/5696 cGy
75%/6000 cGy
CR
CR

W → W
W → B
23.0 LDLT II 1 5% DOO
8 C 35/5 72%/4861 cGy CR Nonclassic B → W 8.6 CLT IIIA 6 90% DOO
9 A 40/4 79%/5063 cGy PR W → W 62.4 CLT IIIB 5.5 Present NA DOO
10a
b
B
0
50/5
50/5
78%/6410 cGy
76%/6579 cGy
PR
SD

B → W
W → W
40.5 CLT IIIC 3.5 95% liver, lymph nodes, left adrenal gland, DOD
11 C 45/5 75%/6000 cGy PR B → B 11.7 LDLT I 6.5 30% DOO
12 C 47.5/5 72%/6690 cGy SD B → B 2.1 CLT No viable tumor NED
13 B 28/5 76%/3683 cGy SD B → B 6.2 NA NA NA NA NA Solitary lung NED
14 D 50/5 90%/5853 cGy CR W → W 8.3 CLT IA 1.5 Present NA NED
  1. B, beyond Milan criteria; BCLC, Barcelona clinic liver cancer; CLT, cadaveric liver transplantation; CR, complete response; DOD, died of disease; DOO, dead of other causes; LDLT, living donor liver transplantation; LT, liver transplantation; NA, not available; NED, no evidence of disease; PR, partial response; PVTT, portal vein tumor thrombosis; RILD, radiation-induced liver disease; SD, stable disease; W, within Milan criteria